HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected for oral and poster presentations on its diabetes product candidates, TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. The symposia will take place from April 17 – 20, 2016 in La Jolla, CA.
